But there are novel challenges, too
It is important to distinguish between urinary changes related to GLP-1 therapy and those caused by other diabetes medications, particularly SGLT2 inhibitors (such as dapagliflozin, empagliflozin), which do directly increase urination as their primary mechanism of action
GLP-1R are expressed by neurons, glia cells do not express this receptor but induced expression when activated in an inflammatory response (17, 25)
What they cannot do is tell you whether you have telogen effluvium, iron deficiency, thyroid-related loss, or underlying androgenetic alopecia
The two peptides are also not the same kind of molecule
As for interleukin, IL-17 and IL-1b act by inhibiting cell-specific melanosomal proteins and activating T helper-17 cells, which increase cell damage by causing mitochondrial dysfunction [19]